Skip to main content

Table 2 Univariate analysis for overall survival and progression free survival in patients with PTCL-NOS

From: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

  Median OS, months HR (95% CI) P-value Median PFS, months HR (95% CI) P-value
Age       
   < 60 years 69.4 1.54 (0.92-2.58) 0.100 11.9 1.00 (0.62-1.62) 0.976
   ≥ 60 years 18.9    13.8   
Gender       
   Male 30.0 1.24 (0.73-2.11) 0.422 12.1. 0.91 (0.55-1.51) 0.732
   Female 27.5    15.2   
Performance status       
   0-1 57.4 4.09 (2.10-8.00) < 0.001 14.5 2.28 (1.16-4.46) 0.016
   2-4 6.3    3.6   
B symptom       
   Absent 38.5 1.45 (0.84-2.50) 0.178 14.7 1.31 (0.79-2.16) 0.282
   Present 15.6    7.1   
Stage       
   1-2 69.4 1.63 (0.93-2.87) 0.086 19.1 1.68 (1.02-2.77) 0.041
   3-4 16.6    9.5   
Extranodal involvement       
   0-1 69.4 2.10 (1.24-3.54) 0.005 18.1 2.08 (1.29-3.35) 0.003
   ≥ 2 11.5    8.1   
Bone marrow involvement       
   Negative 57.4 1.62 (0.93-2.79) 0.084 14.5 1.68 (1.02-2.76) 0.039
   Positive 10.2    7.3   
LDH       
   Normal NR 2.89 (1.67-5.00) < 0.001 16.0 1.69 (1.06-2.68) 0.025
   Elevated 11.5    8.8   
IPI       
   L, LI NR 3.96 (2.36-6.66) < 0.001 18.1 2.34 (1.47-3.74) < 0.001
   HI, H 8.1    8.1   
PIT       
   Group 1-2 76.1 2.78 (1.67-4.62) < 0.001 15.2 1.69 (1.06-2.69) 0.026
   Group 3-4 10.1    9.4   
ALC       
   ≥ 1.0 × 109/l 69.4 2.19 (1.30-3.67) 0.003 18.1 3.01 (1.14-3.02) 0.012
   < 1.0 × 109/l 15.5    7.0   
  1. LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; ALC, absolute lymphocyte count; NR, not reached; OS, overall survival; PFS, progression free survival.